Broadly Neutralizing Antibodies

Neutralizing antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent (e.g., HIV) by targeting several epitopes.

Also Known As:

Antibodies, Broad Neutralizing; Antibodies, Broad Spectrum; Antibodies, Broadly Neutralizing; Antibodies, Cross-Neutralizing; Antibody, Broad Neutralizing; Antibody, Broadly Neutralizing; Antibody, Cross-Neutralizing; Cross Neutralizing Antibodies; Cross Neutralizing Antibody; Neutralizing Antibodies, Broad; Neutralizing Antibodies, Broadly; Neutralizing Antibody, Broad; Neutralizing Antibody, Broadly; Spectrum Antibodies, Broad; Broad Neutralizing Antibodies; Broad Neutralizing Antibody; Broad Spectrum Antibodies; Broadly Neutralizing Antibody; Cross-Neutralizing Antibodies; Cross-Neutralizing Antibody; bnAb; bnAbs

Networked: 786 relevant articles (85 outcomes, 98 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        Broadly Neutralizing Antibodies: 786
        bezlotoxumab: 93
        patritumab: 24
        actoxumab: 12
        suvratoxumab: 9
        dusigitumab: 6
        2F5 monoclonal antibody: 4
        AVP-21D9: 4
        carlumab: 4
        Fletikumab: 4
        2G12 monoclonal antibody: 2
        4Dm2m: 2
        BIIB023: 2
        4E10 monoclonal antibody: 1
        PB-2452: 1
        3BNC117 antibody
        64Cu-DOTA-patritumab
        AR4A cross-neutralizing monoclonal antibody
        CF172 antibody
        VIS410 monoclonal antibody
        VRC01 monoclonal antibody
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        Broadly Neutralizing Antibodies: 786
        bezlotoxumab: 93
        patritumab: 24
        actoxumab: 12
        suvratoxumab: 9
        dusigitumab: 6
        2F5 monoclonal antibody: 4
        AVP-21D9: 4
        carlumab: 4
        Fletikumab: 4
        2G12 monoclonal antibody: 2
        4Dm2m: 2
        BIIB023: 2
        4E10 monoclonal antibody: 1
        PB-2452: 1
        3BNC117 antibody
        64Cu-DOTA-patritumab
        AR4A cross-neutralizing monoclonal antibody
        CF172 antibody
        VIS410 monoclonal antibody
        VRC01 monoclonal antibody
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Neutralizing Antibodies: 9981
        Broadly Neutralizing Antibodies: 786
        bezlotoxumab: 93
        patritumab: 24
        actoxumab: 12
        suvratoxumab: 9
        dusigitumab: 6
        2F5 monoclonal antibody: 4
        AVP-21D9: 4
        carlumab: 4
        Fletikumab: 4
        2G12 monoclonal antibody: 2
        4Dm2m: 2
        BIIB023: 2
        4E10 monoclonal antibody: 1
        PB-2452: 1
        3BNC117 antibody
        64Cu-DOTA-patritumab
        AR4A cross-neutralizing monoclonal antibody
        CF172 antibody
        VIS410 monoclonal antibody
        VRC01 monoclonal antibody

Experts

1.	Mascola, John R: 49 articles (01/2022 - 11/2009)
2.	Nussenzweig, Michel C: 34 articles (04/2022 - 12/2012)
3.	Seaman, Michael S: 34 articles (01/2022 - 12/2012)
4.	Burton, Dennis R: 32 articles (02/2022 - 05/2002)
5.	Morris, Lynn: 32 articles (01/2022 - 11/2009)
6.	Montefiori, David C: 31 articles (01/2022 - 02/2012)
7.	Haynes, Barton F: 30 articles (11/2021 - 09/2010)
8.	Wilson, Ian A: 26 articles (02/2022 - 12/2011)
9.	Moore, Penny L: 24 articles (01/2022 - 11/2009)
10.	Ward, Andrew B: 18 articles (02/2022 - 09/2012)

Related Diseases

1.	Infections 10/07/2013 - "The most convincing data suggesting that NAbs might confer protection against HIV-1 infection have been obtained by experiments of passive immunization of newborn macaques with the first generation of human monoclonal broadly neutralizing antibodies (HuMoNAbs). " 06/08/2021 - "Interestingly, we found that B.1.1.7 infection also generates a cross-neutralizing antibody response, which, although still less potent against B.1.351, can neutralize parental wave 1 virus to a similar degree as B.1.1.7. " 12/17/2014 - "In the past five years, however, new, more potent broadly neutralizing antibodies that do not exhibit autoreactivity properties have been isolated from HIV-1 infected individuals, suggesting that vaccination strategies aimed at producing such broadly neutralizing antibodies may confer protection against infection. " 01/01/2014 - "It also implies the marked improvements in in vitro neutralization potency of many recently discovered bnAb may not translate to comparable reduction in the bnAb dose needed to confer protection against initial vaginal infections. " 01/01/2008 - "The study of large cohorts of individuals enrolled during primary HIV-1 infection using high-throughput immunoassays, sequencing of the virus and the host, and new statistical tools may help to elucidate the pathways of viral escape, to elicit broadly neutralizing antibody responses, and to suggest means of minimizing the impact of HIV-1 on humoral immunity."
2.	HIV Infections (HIV Infection) 05/01/2015 - "This article discusses the effects of early ART and bNAbs on HIV reservoirs and proposes research strategies in acute HIV infection aiming at HIV reservoir reduction and HIV remission." 05/01/2015 - "The acute HIV infection period represents a unique opportunity to explore the use of bNAbs with ART to limit the reservoir seeding that may enhance the chance of HIV remission. " 05/01/2015 - "Broadly neutralizing antibody and the HIV reservoir in acute HIV infection: a strategy toward HIV remission?" 01/01/2021 - "This data is important for the planning and analysis of clinical trials that seek to evaluate bNAbs for the treatment and prevention of HIV infection in Africa." 11/01/2014 - "Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection."
3.	Viremia 01/01/2018 - "This bnAb's breadth and potency were highly effective in protection and treatment settings, as measured by complete viremia control following direct infusion, as well as elimination of infected cells and delay in viral rebound when delivered with a recombinant vector. " 01/01/2022 - "Here, we assess the efficacy of using immunoPET imaging to characterize HIV reservoirs and identify anatomical foci of persistent viral transcriptional activity using a radiolabeled HIV Env-specific broadly neutralizing antibody, 89Zr-VRC01, in HIV-infected individuals with detectable viremia and on suppressive ART compared to uninfected controls (NCT03729752). " 01/01/2023 - "Recent studies in promising clinical trials have shown that, in addition to controlling viremia, anti-HIV-1 bNAbs are able to enhance the host's humoral and cellular immune response. " 10/21/2022 - "Plasma viremia dropped by more than 100-fold in viremic animals after the initial bNAb treatment. " 01/01/2022 - "Here, a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. "
4.	Shock 01/01/2020 - "Clinical trials testing the effect of a single intervention such as a LRA 'shock and kill', immune modulator or bNAbs among HIV-1 infected individuals on long-term suppressive ART have not lead to long-term HIV-1 remission when ART is stopped. " 01/01/2023 - "Based on vectored immunoprophylaxis (VIP) experiment that can elicit bNAbs, in this paper a mathematical model is formulated to explore the efficacy of "shock and kill" strategy with VIP. " 01/01/2020 - "The question remains whether bNAbs and HIV-1 inhibitors will be the effective "kill" to a shock-and-kill approach to eliminate the viral reservoir. " 03/01/2020 - "These efforts included, but are not limited to, broadly neutralizing antibodies, "shock" and "kill" latency-reversing agents, innate immune regulators, and sequential long-acting antiretroviral nanoformulated prodrugs and CRISPR-Cas9 gene editing. " 01/01/2020 - "Other strategies that have been evaluated for achieving sterilizing cure or functional cure--ie, sustained virologic remission in the absence of antiretroviral therapy (ART)-include: HSCT with wild-type CC chemokine receptor (CCR5); early ART to limit size of the HIV latent reservoir; shock and kill strategies using latency reversing agents and/or anti-HIV broadly neutralizing antibodies; and gene therapy, including attempts to modify CCR5 genes, HIV proviruses in autologous host cells, or enhanced T cells. "
5.	Human Influenza (Influenza) 07/01/2013 - "Here we demonstrate that adeno-associated viruses (AAV) encoding two such broadly neutralizing antibodies are protective against diverse influenza strains. " 01/01/2018 - "In this study, we utilized the three-dimensional crystallographic structure of different HA subtypes (H1, H2, H5, H3, and H7) in complex with bNAb to screen for potential broadly reactive influenza inhibitors. " 03/01/2016 - "Using a single-ascending dose study (n = 41) at dose levels from 2 mg/kg-50 mg/kg we evaluated the safety as well as the serum and upper respiratory pharmacokinetics of a broadly-neutralizing antibody (VIS410) against influenza A (ClinicalTrials.gov identifier NCT02045472). " 11/28/2023 - "Stringent and complex sequence constraints of an IGHV1-69 broadly neutralizing antibody to influenza HA stem." 10/01/2023 - "Here, we analyze the landscape by which an anti-influenza receptor binding site (RBS) bnAb, CH65, evolved broad affinity to diverse H1 influenza strains. "

Related Drugs and Biologics

1.	Broadly Neutralizing Antibodies
2.	Vaccines
3.	Antibodies
4.	Neutralizing Antibodies
5.	Epitopes
6.	Glycoproteins (Glycoprotein)
7.	Hemagglutinins (Hemagglutinin)
8.	Antigens
9.	Complement System Proteins (Complement)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Therapeutics
2.	Art Therapy
3.	Intravenous Administration
4.	Cell- and Tissue-Based Therapy (Cell Therapy)
5.	Liver Transplantation